LYSOGENE: LYS-SAF302 is delivering milestones well on track | CORPORATE | EUR11(+338%)
LYSOGENE - CORPORATE | EUR11(+338%)LYS-SAF302 is delivering milestones well on track
The good news of a Fast Track designation for LYS-SAF302
LYS-SAF302 could reach EUR300m sales at peak
Lysogene is the most clinically advanced company for MPSIII
An agreement with Sarepta to secure the development funding
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.